SEC Comment Letter 0000000000-24-011508 to Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
Date: Oct. 10, 2024 · CIK: 0001841330 · Accession: 0000000000-24-011508
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282532
Letter
October 10, 2024 Tiago Reis Marques Chief Executive Officer Pasithea Therapeutics Corp. 1111 Lincoln Road, Suite 500 Miami Beach, FL 33139 Re:Pasithea Therapeutics Corp. Registration Statement on Form S-3 Filed October 7, 2024 File No. 333-282532 Dear Tiago Reis Marques: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Tracy Buffer, Esq.
Show Raw Text
October 10, 2024
Tiago Reis Marques
Chief Executive Officer
Pasithea Therapeutics Corp.
1111 Lincoln Road, Suite 500
Miami Beach, FL 33139
Re:Pasithea Therapeutics Corp.
Registration Statement on Form S-3
Filed October 7, 2024
File No. 333-282532
Dear Tiago Reis Marques:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Tracy Buffer, Esq.